Mallia Therapeutics Presents Findings on sCD83 for Wound Healing

Mallia Therapeutics has announced a publication in "Wound Repair and Regeneration" highlighting the regenerative potential of soluble CD83 (sCD83) in improving chronic wound healing. This study, conducted by researchers at Uniklinikum Erlangen, demonstrates that sCD83 can address immune dysregulation, a core issue in healing chronic wounds.

The research will be presented at the joint conference of the European Wound Management Association (EWMA) and the German Wound Congress (DEWU). The study indicates sCD83's role in accelerating wound closure by modulating macrophages and reducing inflammation.

This breakthrough points to a new therapeutic approach for chronic wounds, addressing long-standing medical needs through immunomodulation and enhanced tissue repair processes. sCD83's effects were tested using a human 3D wound model, demonstrating its capabilities even in challenging inflammatory conditions.